Revolution Medicines (NASDAQ:RVMD) Stock Rating Reaffirmed as “Buy” by Truist Financial

Revolution Medicines (NASDAQ:RVMD)‘s stock had its “buy” rating restated by stock analysts at Truist Financial in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $261.00 price objective on the stock, up from their previous price objective of $241.00. Truist Financial‘s price objective would indicate a potential upside of 35.74% from the stock’s previous close.

RVMD has been the topic of a number of other research reports. The Goldman Sachs Group assumed coverage on Revolution Medicines in a research note on Thursday, September 24th. They set a “buy” rating and a $267.00 price objective on the stock. Royal Bank Of Canada raised their target price on Revolution Medicines from $259.00 to $260.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 14th. Oppenheimer lifted their price target on Revolution Medicines from $230.00 to $260.00 and gave the stock an “outperform” rating in a report on Thursday, August 27th. Brookline Capital Markets began coverage on shares of Revolution Medicines in a research report on Monday, September 28th. They set a “buy” rating and a $318.00 price target on the stock. Finally, TD Cowen reissued a “buy” rating and set a $250.00 price target on shares of Revolution Medicines in a research report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $263.15.

Revolution Medicines Price Performance

RVMD traded up $14.63 during trading on Thursday, reaching $192.28. The company’s stock had a trading volume of 4,496,326 shares, compared to its average volume of 1,940,895. The company has a market cap of $41.21 billion, a price-to-earnings ratio of -21.11 and a beta of 1.44. The firm has a fifty day simple moving average of $196.88 and a two-hundred day simple moving average of $157.56. Revolution Medicines has a 1 year low of $58.91 and a 1 year high of $224.31. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.35) by $0.45. The company had revenue of $197.56 million during the quarter, compared to analysts’ expectations of $25.58 million. During the same quarter last year, the company earned ($1.61) earnings per share. As a group, analysts anticipate that Revolution Medicines will post -8.94 EPS for the current year.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, insider Alan Sandler sold 6,309 shares of the stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $202.14, for a total value of $1,275,301.26. Following the sale, the insider owned 52,559 shares of the company’s stock, valued at $10,624,276.26. This trade represents a 10.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Jack Anders sold 4,053 shares of the firm’s stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $199.24, for a total transaction of $807,519.72. Following the completion of the sale, the chief financial officer directly owned 119,216 shares in the company, valued at approximately $23,752,595.84. This trade represents a 3.29% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 290,991 shares of company stock valued at $59,422,765. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

Large investors have recently bought and sold shares of the stock. Alphabet Inc. acquired a new stake in shares of Revolution Medicines in the 2nd quarter valued at about $551,843,000. Assenagon Asset Management S.A. increased its position in Revolution Medicines by 987.9% during the third quarter. Assenagon Asset Management S.A. now owns 2,181,185 shares of the company’s stock worth $447,710,000 after buying an additional 1,980,699 shares during the period. ABS Investment Management LLC acquired a new position in Revolution Medicines during the second quarter worth approximately $337,104,000. Bank of America Corp DE acquired a new position in Revolution Medicines during the second quarter worth approximately $184,267,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Revolution Medicines by 82.3% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 912,335 shares of the company’s stock valued at $170,862,000 after buying an additional 411,740 shares during the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Strong early Rasonque sales: Revolution Medicines reported $197.6 million in third-quarter revenue, beating estimates, with Rasonque generating that amount in just five weeks after its U.S. launch. The company said more than 5,000 patients had been treated. The quarterly loss per share also came in narrower than analysts expected. Zacks article on Q3 results and Rasonque uptake
• Positive Sentiment: Analyst targets moved higher: HC Wainwright raised its target to $350 and maintained a Buy rating. RBC lifted its target to $321 with an Outperform rating; Guggenheim, Truist and TD Cowen also raised targets and retained positive ratings. These revisions signal optimism about the drug’s commercial potential and pipeline. HC Wainwright recommendations RBC target increase
• Neutral Sentiment: Long-term opportunity, but expectations are high: Rasonque’s clinical results and potential expansion into other solid tumors support the pipeline outlook. However, commentary noted that RVMD’s roughly $40 billion valuation already reflects substantial expectations, making sustained launch growth and upcoming clinical results important. Seeking Alpha analysis of Q3 results
• Negative Sentiment: Some long-range forecasts were cut: Brookline Capital Markets lowered its FY2029 EPS estimate to $8.49 from $8.94 and its FY2030 estimate to $17.41 from $18.15, though it kept a Buy rating and a $318 target.

About Revolution Medicines

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers.

The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.